Long-term plasmapheresis and protein A column treatment of recurrent FSGS.
Transient or intermittent plasmapheresis with concurrent immunosuppressive therapy is thought to be beneficial in the treatment of recurrent focal segmental glomerulosclerosis (FSGS) in the early post-transplant period. The results of long-term (6-year) plasmapheresis therapy, in a 9-year-old female with an immediate recurrence of FSGS [urinary protein/urinary creatinine (UP/UC)=17.7] after cadaveric renal transplant, are presented. A 4-week plasmapheresis course induced a decline in the proteinuria, but a relapse occurred after cessation of plasmapheresis. Addition of protein A column therapy led to a further decrease in the proteinuria, to a non-nephrotic range. Long-term control of the nephrotic syndrome was established using a chronic treatment regimen consisting of a single-volume plasmapheresis, followed by a protein A column treatment, performed on sequential days every 3-4 weeks. Mean UP/UC values decreased to 1.15+/-0.9. A course of cyclophosphamide was successfully used to control a worsening of proteinuria 4 years post transplant. Although sequential renal biopsies demonstrated progressive glomerular sclerosis, the patient's mean calculated creatinine clearance only modestly declined from 78.3 ml/min per 1.73 m2, at the time of transplantation, to 62.7 ml/min per 1.73 m2, 6 years later. This patient demonstrated dependence on plasmapheresis/protein A column therapy to maintain a clinical remission of her FSGS recurrence. While long-term plasmapheresis and protein A column therapy in combination with immunosuppressive therapy reversed the effects of uncontrolled nephrosis and possibly facilitated long-term renal allograft survival, the glomerular sclerosis continued to progress.
Belson
A
A
Department of Pediatrics, Section of Pediatric Nephrology, Lucile Salter Packard Children's Hospital, Stanford University, Stanford, CA 94305, USA. abelson@stanford.edu
Yorgin
P D
PD
Al-Uzri
A Y
AY
Salvatierra
O
O
Higgins
J
J
Alexander
S R
SR
D002648:Child; D005260:Female; D005923:Glomerulosclerosis, Focal Segmental / Q000628:therapy*; D006801:Humans; D016030:Kidney Transplantation; D010956:Plasmapheresis; D012008:Recurrence; D013205:Staphylococcal Protein A / Q000627:therapeutic use*; D013997:Time Factors
D013205:Staphylococcal Protein A